Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Minor: EP-104GI · Eosinophilic Esophagitis (EoE) Trial sites expanded: 23 → 33 locations Eupraxia Pharmaceuticals Inc.Phase 1/2 NCT05608681
  2. Minor: Afimkibart · Rheumatoid Arthritis Trial sites expanded: 10 → 17 locations Hoffmann-La RochePhase 2 NCT07620392
  3. Minor: LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy Trial sites expanded: 1 → 22 locations Lexeo TherapeuticsPhase 2 NCT07721025
  4. Minor: EPI-326 in EGFR-mutant NSCLC and HNSCC Trial sites expanded: 6 → 12 locations EpiBiologicsPhase 1 NCT07462377
  5. Minor: Methylene Blue Photodynamic Therapy · Deep Tissue Abscesses Enrollment increased: 120 → 150 participants University of RochesterPhase 2 NCT06052956
  6. Minor: S241656 in Selected RAS/MAPK Mutation- Positive Malignancies Enrollment increased: 554 → 623 participants Institut de Recherches Internationales ServierPhase 1/2 NCT05786924
  7. Minor: VIR-5500 (AMX-500) in Prostate Cancer Trial sites expanded: 26 → 30 locations Astellas Pharma Global Development, Inc.Phase 1 NCT05997615
  8. Minor: CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) Trial sites expanded: 4 → 15 locations Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Phase 1 NCT07300085
  9. Minor: Carnosine · Peripheral Arterial Disease Patients Enrollment reduced: 144 → 120 participants Shahid BabaPhase 1/2 NCT06480760
  10. Minor: TOS-358 · HR+ HER2- Breast Cancer Trial sites expanded: 18 → 25 locations Totus MedicinesPhase 1 NCT05683418
  11. Minor: Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry Trial sites expanded: 318 → 324 locations Genzyme, a Sanofi CompanyNot specified NCT00358943
  12. Minor: Antitumor Activity of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma Enrollment increased: 9 → 10 participants Ruijin HospitalPhase 1 NCT07885306
  13. Minor: Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain Trial sites expanded: 1 → 5 locations Novartis PharmaceuticalsNot specified NCT07598448
  14. Minor: How Elinzanetant is Used and How Well it Works · Menopause Symptoms Trial sites expanded: 0 → 22 locations BayerNot specified NCT07490431
  15. Minor: Fabry Disease Registry & Pregnancy Sub-registry Trial sites expanded: 284 → 289 locations Genzyme, a Sanofi CompanyNot specified NCT00196742
  16. Minor: MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study Trial sites expanded: 2393 → 2449 locations Stryker InstrumentsNot specified NCT03072927
  17. Minor: NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage Enrollment increased: 280 → 384 participants Southwest Hospital, ChinaNot applicable NCT06894433
  18. Minor: Molecular and Imaging Studies of Cardiovascular Health and Disease Enrollment increased: 5000 → 6000 participants National Heart Centre SingaporeNot specified NCT02804269
  19. Minor: Apalutamide (ARN-509) · Non-Metastatic Castration-Resistant Prostate Cancer Study completion pushed from Dec 31, 2027 to Dec 31, 2029 Aragon Pharmaceuticals, Inc.Phase 3 NCT01946204
  20. Minor: Subcutaneous Nomlabofusp · Friedreich's Ataxia Start date changed from estimate of Oct 26, 2026 to Aug 5, 2026 Larimar Therapeutics, Inc.Phase 3 NCT07778836
  21. Minor: Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy Start date pushed from Nov 9, 2026 to Nov 30, 2026 Grünenthal GmbHPhase 2 NCT07911995
  22. Minor: Erdafitinib (JNJ-42756493) · Urothelial Cancer Study completion pushed from Mar 31, 2027 to Dec 31, 2027 Janssen Research & Development, LLCPhase 2 NCT02365597
  23. Minor: VG2025 Intravenous Injection · Advanced Solid Tumors Start date changed from estimate of Sep 4, 2026 to Nov 11, 2026 Virogin Biotech Ltd.Phase 1/2 NCT07682870
  24. Minor: ALKS 7290 as an Adjunctive Therapy to Antidepressants · Major Depressive Disorder Start date changed from estimate of Oct 2026 to Nov 9, 2026 Alkermes, Inc.Phase 2 NCT07901179
  25. Minor: Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy · Active Crohn's Disease Trial sites expanded: 4 → 7 locations James LewisNot applicable NCT07356232